Differences in the expression profiles of excision repair crosscomplementation group 1, X-ray repair crosscomplementation group 1, and βiII-Tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival

Journal of Thoracic Oncology

Volumn 4, Issue 11, 2009, Pages 1307-1312

  Kang, Chang Hyun ^a   Jang, Bo Gun ^a   Kim, Dong Wan ^b   Chung, Doo Hyun ^a   Kim, Young Tae ^a   Jheon, Sanghoon ^c   Sung, Sook Whan ^c   Kim, Joo Hyun ^a  

^a Department of Thoracic and Cardiovascular Surgery ^*  (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

Author keywords

Adjuvant; Carcinoma; Chemotherapy; Drug resistance; Neoplasm; Non small cell; Thoracic surgical procedures

Indexed keywords

BETA III TUBULIN; BETA TUBULIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL TYPE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 70449572285     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181b9f236     Document Type: Article

References (20)

1. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
2. Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung cancer 2005;50:227-234.
3. Kang CH, Ra YJ, Kim YT, Jheon SH, Sung SW, Kim JH. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer. Ann Thorac Surg 2008;86: 1092-1097.
4. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. New Engl J Med 2004;350:351-360.
5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet oncol 2006;7:719-727.
6. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8: 193-204.
7. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-2291.
8. Lee KH, Min HS, Han SW, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung cancer 2008;60:401-407.
9. Rosell R, Mendez P, Isla D, Taron M. Platinum resistance related to a functional NER pathway. J Thorac Oncol 2007;2:1063-1066.
10. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New Engl J Med 2006;355:983-991.
11. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-265.
12. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-smallcell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 1999;17:1786-1793.
13. Cobo M, Isla D, Massuti B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25:2747-2754.
14. Williams BA, Sugimura H, Endo C, et al. Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients. Ann Thorac Surg 2006;81:1021-1027.
15. Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer 2006;6:141-146.
16. Ward RJ, Dirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2007;2:175-189.
17. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45: 872-877.
18. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
19. Katsetos CD, Herman MM, Mork SJ. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003;55:77-96.
20. Katsetos CD, Kontogeorgos G, Geddes JF, et al. Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 2000;124:535-544.